Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy

By sjmartinez • June 3, 2024

Miller JE, Taylor-Cousar JL, Overdevest JB, Khatiwada A, Mace JC, Alt JA, Bodner TE, Chowdhury NI, DiMango EA, Eshaghian PH, Getz AE, Gudis DA, Han EJ, Hwang PH, Keating CL, Khanwalkar A, Kimple AJ, Lee JT, Li D, Markarian K, Norris M, Nayak JV, Owens C, Patel ZM, Poch K, Schlosser RJ, Smith KA, Smith TL, Soler ZM, Suh JD, Tervo JP, Turner GA, Wang MB, Saavedra MT, Beswick DM. Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy. Int Forum Allergy Rhinol. 2024 Jun;14(6):1079-1087. doi: 10.1002/alr.23312. Epub 2023 Dec 25. PMID: 38145393.

Tags: chronic rhinosinusitis, cystic fibrosis, highly effective modulator therapy, olfaction, olfactory disorders, olfactory dysfunction, olfactory test, patient‐reported outcome measure, Publications, Pulmonary, Critical Care & Sleep Medicine, Quality of Life

Authors’ Reply on Immune-Mediated Liver Injury in HCC

Ennin E, Mallepally N, Dodge JL, Dara L. Authors' Reply on Immune-Mediated Liver Injury in HCC. Liver Int. 2025 Nov;45(11):e70415. doi: 10.1111/liv.70415. PMID: 41122960.

Oliceridine: Examining the clinical evidence, pharmacology, and contested mechanism of action of the first FDA-approved biased opioid agonist

Prommer EE. Oliceridine: Examining the clinical evidence, pharmacology, and contested mechanism of action of the first FDA-approved biased opioid agonist. J Opioid Manag. 2025 Sep-Oct;21(5):377-387.[...]

Analyses of adverse events and patient-reported outcomes with the toxicity index in cancer clinical trials

Gresham G, Henry NL, Bandos H, Calsavara VF, Cecchini RS, Diniz MA, Hays RD, Luu M, Kim S, Rogatko A, Yothers G, Ganz PA, Tighiouart[...]